380 related articles for article (PubMed ID: 37947195)
1. Psychedelics for treatment resistant depression: are they game changers?
Kalfas M; Taylor RH; Tsapekos D; Young AH
Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
[TBL] [Abstract][Full Text] [Related]
2. Role of Psychedelics in Treatment-Resistant Depression.
Kamal S; Jha MK; Radhakrishnan R
Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
[TBL] [Abstract][Full Text] [Related]
3. The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
Zaretsky TG; Jagodnik KM; Barsic R; Antonio JH; Bonanno PA; MacLeod C; Pierce C; Carney H; Morrison MT; Saylor C; Danias G; Lepow L; Yehuda R
Curr Neuropharmacol; 2024; 22(4):636-735. PubMed ID: 38284341
[TBL] [Abstract][Full Text] [Related]
4. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
[TBL] [Abstract][Full Text] [Related]
5. Drug-drug interactions involving classic psychedelics: A systematic review.
Halman A; Kong G; Sarris J; Perkins D
J Psychopharmacol; 2024 Jan; 38(1):3-18. PubMed ID: 37982394
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
[TBL] [Abstract][Full Text] [Related]
7. Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.
Madrid-Gambin F; Fabregat-Safont D; Gomez-Gomez A; Olesti E; Mason NL; Ramaekers JG; Pozo OJ
Biomed Pharmacother; 2023 Dec; 169():115775. PubMed ID: 37944438
[TBL] [Abstract][Full Text] [Related]
8. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
[TBL] [Abstract][Full Text] [Related]
9. Dosing Psychedelics and MDMA.
Liechti ME; Holze F
Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
[TBL] [Abstract][Full Text] [Related]
10. Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
Am J Ther; 2024 Mar-Apr 01; 31(2):e97-e103. PubMed ID: 38518266
[TBL] [Abstract][Full Text] [Related]
11. Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.
Holze F; Singh N; Liechti ME; D'Souza DC
Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):472-489. PubMed ID: 38301886
[TBL] [Abstract][Full Text] [Related]
12. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
Sousa TR; Rema J; Machado S; Novais F
Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
[TBL] [Abstract][Full Text] [Related]
13. Human behavioral pharmacology of psychedelics.
Strickland JC; Johnson MW
Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
[TBL] [Abstract][Full Text] [Related]
14. Psychedelics and Psychedelic-Assisted Psychotherapy.
Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
[TBL] [Abstract][Full Text] [Related]
15. The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits.
Videira NB; Nair V; Paquet V; Calhoun D
J Appl Toxicol; 2024 Feb; 44(2):216-234. PubMed ID: 37646119
[TBL] [Abstract][Full Text] [Related]
16. Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies.
Calleja-Conde J; Morales-García JA; Echeverry-Alzate V; Bühler KM; Giné E; López-Moreno JA
Addict Biol; 2022 Nov; 27(6):e13229. PubMed ID: 36301215
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
[TBL] [Abstract][Full Text] [Related]
18. The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.
Mastinu A; Anyanwu M; Carone M; Abate G; Bonini SA; Peron G; Tirelli E; Pucci M; Ribaudo G; Oselladore E; Premoli M; Gianoncelli A; Uberti DL; Memo M
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674849
[TBL] [Abstract][Full Text] [Related]
19. The use of classic psychedelics among adults: a Danish online survey study.
Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A
Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202
[TBL] [Abstract][Full Text] [Related]
20. Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways.
Sinha JK; Trisal A; Ghosh S; Gupta S; Singh KK; Han SS; Mahapatra M; Abomughaid MM; Abomughayedh AM; Almutary AG; Iqbal D; Bhaskar R; Mishra PC; Jha SK; Jha NK; Singh AK
Ageing Res Rev; 2024 Apr; 96():102211. PubMed ID: 38307424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
